Reviews in molecular medicine: Familial Creutzfeldt-Jakob disease Codon 200 prion disease in Libyan Jews

Medicine

Volumn 76, Issue 4, 1997, Pages 227-237

  Maher, Eamonn R ^a   Kaelin Jr , William G ^b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODON; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; HIGH RISK POPULATION; HUMAN; JEW; LIBYAN ARAB JAMAHIRIYA; PRION DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0343852762     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199707000-00001     Document Type: Review

References (107)

1. Aso T, Haque D, Barstead R, Conaway R, Conaway J. The inducible elongin A elongation activation domain: Structure, function and interaction with elongin BC complex. EMBO J 15: 101-110, 1996.
2. Aso T, Lane WS, Conaway JW, Conaway RC. Elongin (SIII): A multi-subunit regulator of elongation by RNA polymerase II. Science 269: 1439-43, 1995.
3. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86: 263-74, 1996.
4. Berse B, Brown L, Livingston V, Dvorak H, Senger D. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3: 211-20, 1992.
5. Binkovitz L, Johnson C, Stephens D. Islet cell tumors in von Hippel-Lindau disease: Increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol 155: 501-5, 1990.
6. Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, Lerman MI, Zbar B, Neumann HPH. von Hippel-Lindau disease with pheochromocytoma in the Black Forest region in Germany: Evidence for a founder effect. Hum Genet 95: 551-56, 1995.
7. Chen F, Kishida T, Dun F-M, Renbaum P, Orcutt ML, Schmidt L, Zbar B. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55: 4804-7, 1995.
8. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Ming HW, Schmidt L, Kalman T, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 5: 66-75, 1995.
9. Chen F, Slife L, Kishida T, Mulvihill S, Tisherman E, Zbar B. Genotype-phenotype correlation in von Hippel-Lindau disease: Identification of a mutation associated with VHL type 2A. J Med Genet 33: 716-17, 1996.
10. Chen L, Burridge K, Murray A, Walsh M, Copple C, Bushnell A, McDougall J, Gallimore P. Modulation of cell surface glycocalyx: Studies on large, external, transformation-sensitive protein. Ann N Y Acad Sci 312: 366-81, 1978.
11. Choyke P, Glenn G, Walther M, Zbar B, Weiss G, Alexander RB, Hayes W, Long J, Thakore K, Linehan W. The natural history of renal lesions in von Hippel-Lindau disease: A serial CT study in 28 patients. AJR Am J Roentgenol 159: 1229-34, 1992.
12. Collins ET. Intraocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc U K 14: 141-49, 1894.
13. Corless CL, Kibel A, Iliopoulos O, Kaelin WG Jr. Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Hum Pathol 28: 459-64, 1997.
14. Crossey P, Eng C, Ginalska-Malinowska M, Lennard T, Wheeler D, Ponder B, Maher E. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet 32: 885-86, 1995.
15. Crossey P, Foster K, Richards F, Phipps M, Latif F, Tory K, Jones M, Bentley E, Kumar R, Lerman M, Zbar B, Affara N, Ferguson-Smith M, Maher E. Molecular genetic investigation of the mechanism of tumourigenesis in von Hippel-Lindau disease: Analysis of allele loss in VHL tumours. Hum Genet 93: 53-58, 1994.
16. Crossey P, Maher E, Jones M, Richards F, Latif F, Phipps M, Lush M, Foster K, Tory K, Green J, Oostra B, Yates J, Linehan W, Affara N, Lerman M, Zbar B, Nakamura Y, Ferguson-Smith M. Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. Hum Mol Genet 2: 279-82, 1993.
17. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, Maher ER. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Gen 3: 1303-8, 1994.
18. Cushing H, Bailey P. Hemangiomas of cerebellum and retina (Lindau's disease), with a report of a case. Arch Ophthalmol 57: 447-63, 1928.
19. Duan DR, Humphrey JS, Chen DYT, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM, Klausner RD. Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A 92: 6495-99, 1995.
20. Duan DR, Pause A, Burgress W, Aso T, Chen DYT, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD. Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 269: 1402-6, 1995.
21. Eng C, Crossey P, Mulligan L, Healey C, Houghton C, Prowse A, Chew S, Dahia P, O'Riordan J, Toledo S, Smith D, Maher E, Ponder B. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32: 934-37, 1995.
22. Filling-Katz M, Choyke P, Oldfield E, Charnas L, Patronas N, Glenn G, Gorin M, Morgan J, Linehan W, Seizinger BR, et al. Central nervous system involvement in Von Hippel-Lindau disease. Neurology 41: 41-46, 1991.
23. Foster K, Osborne R, Huddart R, Affara N, Ferguson-Smith MA, Maher E. Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours. Eur J Cancer 31A: 2392-95, 1995.
24. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MMF, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys CHCM, Maher ER. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Gen 3: 2169-73, 1994.
25. Fulton JF. Harvey Cushing: A biography. Springfield, Illinois: Charles C Thomas, 1946.
26. Gao J, Naglich JG, Laidlaw J, Whaley JM, Seizinger BR, Kley N. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: Implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res 55: 743-47, 1995.
27. Giancotti F, Mainiero F. Integrin-mediated adhesion and signaling in tumorigenesis. Biochim Biophys Acta 1198: 47-64, 1994.
28. Giancotti FG, Ruoslahti E. Elevated levels of the a5b1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60: 849-59, 1990.
29. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994.
30. Gnarra JR, Zhou S, Merrill MJ, Wagner J, Krumm A, Papavassiliou E, Oldfleld EH, Klausner RD, Linehan WM. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci U S A 93: 10589-94, 1996.
31. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 269: 4355-59, 1994.
32. Golde DW, Hocking WG. Polycythemia: Mechanisms and management. Ann Intern Med 95: 71-87, 1981.
33. Gross D, Avishai N, Meiner V, Filon D, Zbar B, Abeliovich D. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Met 81: 147-49, 1996.
34. Grossniklaus H, Thomas J, Vigneswaran N, Jarrett WH 3d. Retinal hemangioblastoma. A histologic, immunohistochemical, and ultrastructural evaluation. Ophthalmology 99: 140-45, 1992.
35. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan D-SR, Gnarra JR, Linehan WM, Baylin SB. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91: 9700-4, 1994.
36. Hopkin K. Regulating cellular processes: The power of protein degradation. J NIH Res 9: 36-42, 1997.
37. Hosoe S, Brauch H, Latif F, Glenn G, Lambert D, Bale S, Choyke P, Gorin M, Oldfleld E, Berman A, Goodman J, Orcutt ML, Hampsch K, Delisio J, Modi W, McBride W, Anglard P, Weiss G, Walther MM, Linehan WM, Lerman MI, Zbar B. Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8: 634-40, 1990.
38. Hynes R. Integrins: Versatility, modulation, and signalling in cell adhesion. Cell 69: 11-25, 1992.
39. Hynes R, Ali I, Destree A, Mautner V, Perkins M, Senger D, Wagner D, Smith K. A large glycoprotein lost from the surfaces of transformed cells. Ann N Y Acad Sci 312: 317-42, 1978.
40. Iliopoulos O, Jiang C, Levy AP, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93: 10595-99, 1996.
41. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-26, 1995.
42. Jackson PK. Cell cycle: Cull and destroy. Curr Biol 6: 1209-12, 1996.
43. Kaelin WG. Recent insights into the functions of the retinoblastoma gene product. Cancer Invest 15: 243-54, 1997.
44. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, Sakai N, Hosaka M, Shuin T, Yao M. Somatic mutations of the von Hippel-Lindau tumor supressor gene in sporadic central nervous systems hemangioblastomas. Cancer Res 54: 4845-47, 1994.
45. Kessler P, Vasavada S, Rackley R, Stackhouse T, Duh F, Latif F, Lerman M, Zbar B, Williams B. Expression of the von Hippel-Lindau tumor-suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1: 457-66, 1995.
46. Kibel A, Iliopoulos O, DeCaprio JD, Kaelin WG. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269: 1444-46, 1995.
47. Kinzler K, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87: 159-70, 1996.
48. Kipreos ET, Lander LE, Wing JP, He WW, Hedgecock EM. Cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 85: 829-839, 1996.
49. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 55: 4544-48, 1995.
50. Kuzmin I, Dun F-M, Latif F, Geil L, Zbar B, Lerman MI. Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 10: 2185-94, 1995.
51. Lamiell J, Salazar F, Hsia Y. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68: 1-29, 1989.
52. Latif F, Tory K, Gnarra J, Yao M, Duh F-M, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan D-SR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Pasiler DL, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-20, 1993.
53. Lee S, Chen DYT, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A 93: 1770-75, 1996.
54. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 271: 25492-97, 1996.
55. Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaelin WG, Goldberg MA. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 51: 575-78, 1997.
56. Landau A. Zur Frage der Angiomatosis retinae und ihrer Hirncomplikation. Acta Ophthalmol (Copenh) 4: 193-226, 1927.
57. Lipkin G, Knecht M, Rosenberg M. Glycoprotein-containing factor that mediates contact inhibition of growth. Ann N Y Acad Sci 312: 382-91, 1978.
58. Los M, Jansen GH, Kaelin WG, Lips CJM, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75: 231-38, 1996.
59. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149: 2089-94, 1996.
60. Maddock I, Moran A, Maher E, Teare M, Norman A, Payne S, Whitehouse R, Dodd C, Lavin M, Hartley N, Super M, Evans D. A genetic register for von Hippel-Lindau disease. J Med Genet 33: 120-27, 1996.
61. Maher E, Webster AR, Moore A. Clinical features and molecular genetics of von Hippel-Lindau disease. Ophthalmic Genet 16: 79-84, 1995.
62. Maher E, Bentley E, Yates J, Latif F, Lerman M, Zbar B, Affara N, Ferguson-Smith M. Localization of the gene for von Hippel-Lindau disease to a small region of chromosome 3p by genetic linkage analysis. Genomics 10: 957-60, 1991.
63. Maher E, Webster A, Richards F, Green J, Crossey P, Payne S, Moore A. Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations. J Med Genet 33: 328-32, 1996.
64. Maher ER, Yates JRW, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar hemangioblastoma and renal cell carcinoma. J Med Genet 27: 311-14, 1990.
65. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77: 1151-63, 1990.
66. Manski T, Heffher D, Glenn G, Patronas N, Pikus A, Katz D, Lebovics R, Sledjeski K, Choyke P, Zbar B, Linehan W, Oldfleld E. Endolymphatic sac tumors - A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 277: 1461-66, 1997.
67. McKusick VA. Mendelian inheritance in man. 12th ed. Baltimore: Johns Hopkins University Press, 1997.
68. Melmon K, Rosen S. Landau's disease. Am J Med 36: 595-17, 1964.
69. Nakamura Y. Cleaning up on β-catenin. Nat Med 3: 499-509, 1997.
70. Neumann H, Eng C, Mulligan L, Glavac D, Ponder B, Crossey P, Maher E, Brauch H. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia type 2. JAMA 274: 1149-51, 1995.
71. Pasqualini R, Bourdoulous S, Koivunen E, Woods V Jr, Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 2: 1197-1203, 1996.
72. Pause A, Lee S, Worrell RA, Chen DYT, Burgess WH, Linehan WM, Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 94: 2156-61, 1997.
73. Prowse A, Webster A, Richards F, Richard S, Olschwang S, Resche F, Affara N, Maher E. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 60: 765-71, 1997.
74. Renbaum P, Duh F-M, Latif F, Zbar B, Lerman M, Kuzmin I. Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene. Hum Genet 98: 666-71, 1996.
75. Richard S, Chauveau D, Chretien Y, Beigelman C, Denys A, Fendler J, Fromont G, Paraf F, Helenon O, Nizard S, Proye C, Resche F, Plouin P-F. Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol 23: 1-27, 1994.
76. Richards F, Crossey P, Phipps M, Foster K, Latif F, Evans G, Sampson J, Lerman M, Zbar B, Affara N, Ferguson-Smith M, Maher E. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 3: 595-98, 1994.
77. Richards F, Payne S, Zbar B, Affara N, Ferguson-Smith M, Maher E. Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 4: 2139-43, 1995.
78. Richards F, Phipps M, Latif F, Yao M, Crossey P, Foster K, Linehan W, Affara N, Lerman M, Zbar B, Ferguson-Smith M, Maher E. Mapping the von Hippel-Lindau disease tumour suppressor gene: Identification of germline deletions by pulsed field gel electrophoresis. Hum Mol Genet 2: 879-82, 1993.
79. Richards F, Schofield P, Fleming S, Maher E. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5: 639-44, 1996.
80. Richards FM, Maher ER, Latif F, Phipps ME, Tory K, Lush M, Crossey PA, Oostra B, Gustavson KH, Green J, Turner G, Yates JRW, Lineham WH, Affara NA, Lerman M, Zbar B, Ferguson-Smith MA. Detailed genetic mapping of the von Hippel-Lindau disease tumour supressor gene. J Med Genet 30: 104-7, 1993.
81. Sato K, Terada K, Sugiyama T, Takahashi S, Saito M, Moriyama M, Kakinuma H, Suzuki Y, Kato M, Kato T. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J Exp Med 173: 355-60, 1994.
82. Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P, Scherer S, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim U, Feltis J, Casadevall C, Zamarron A, Bernues M, Richard S, Lips C, Walther M, Tsui L, Geil L, Orcutt M, Stackhouse T, Zbar Bea. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 16: 68-73, 1997.
83. Schwartz M. Signaling by integrals: Implications for tumorigenesis. Cancer Res 53: 1503-5, 1993.
84. Seizinger B, Smith D, Filling-Katz M, Neumann H, Green J, Choyke P, Anderson K, Freiman R, Klauck S, Whaley J, Hsia Y, Collins D, Halperin J, Lamiell J, Oostra B, Waziri M, Gorin M, Scherer G, Drabkin H, Aronin N, Schinzel A, Martuza R, Gusella J, Haines J. Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of von Hippel-Lindau disease. Proc Natl Acad Sci U S A 88: 2864-68, 1991.
85. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JWM, Collins D, Majoor-Krakauer D, Bonner T, Mathew C, Rubenstein A, Halperin J, McConkie-Rosell A, Green JS, Trofatter JA, Ponder BA, Eierman L, Bowmer MI, Schimke R, Oostra B, Aronin N, Smith DI, Drabkin H, Waziri MH, Hobbs WJ, Martuza RL, Conneally PM, Hsia YE, Gusella JF. von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268-69, 1988.
86. Sekido Y, Bader S, Latif F, Gnarra J, Gazdar A, Linehan W, Zbar B, Lerman M, Minna J. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 9: 1599-1604, 1994.
87. Sellers WR, Kaelin WG. RB as a modulator of transcription. Biochim Biophys Acta 1288: M1-M5, 1996.
88. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI, Yao M. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-55, 1994.
89. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56: 2299-301, 1996.
90. Steinbach F, Novick A, Zincke H, Miller D, Williams R, Lund G, Skinner D, Esrig D, Richie J, deKernion J. Treatment of renal cell carcinoma in von Hippel-Lindau disease: A multicenter study. J Urol 153: 1812-16, 1995.
91. Takahashi A, Sasaki H, Kim S, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-37, 1994.
92. Teh B, Giraud S, Sari F, Hii S, Bergerat J, Larsson C, Limacher J, Nicol D. Familial non-VHL non-papillary clear-cell renal cancer [letter]. Lancet 349: 848-49, 1997.
93. Tory K, Brauch H, Linehan M, Barba D, Oldfield E, Filling-Katz M, Seizinger B, Nakamura Y, White R, Marshall F. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81: 1097-1101, 1989.
94. Tsuchiya H, Iseda T, Hino O. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res 56: 2881-85, 1996.
95. Vaheri A, Alitalo K, Hedman K, Keski-Oja J, Kurkinen M, Wartiovaara J. Fibronectin and the pericellular matrix of normal and transformed adherant cells. Ann N Y Acad Sci 312: 343-53, 1978.
96. Vance J, Small K, Jones M, Stajich J, Yamaoka L, Roses A, Hung W, Pericak-Vance M. Confirmation of linkage in von Hippel-Lindau disease. Genomics 6: 565-67, 1990.
97. von Hippel E. Ueber eine sehr seltene Erkrankung der Nethaut. Graefes Arch Ophthalmol 59: 83-106, 1904.
98. Walther M, Choyke P, Weiss G, Manolatos C, Long J, Reiter R, Alexander R, Linehan W. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 153(3 Pt 2): 913-16, 1995.
99. Walther M, Lubensky I, Venzon D, Zbar B, Linehan W. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: Clinical implications. J Urol 154: 2010-14, 1995.
100. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81: 323-30, 1995.
101. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS, Collins D, Neumann HPH, Laidlaw J, Li FP, Klein-Szanto AJP, Seizinger BR, Kley N. Germ-line mutations in the von Hippel-Lindau tumor suppressor gene are similar to somatic von Hippel-Lindau abberations in sporadic renal cell carcinoma. Am J Hum Genet 55: 1092-1102, 1994.
102. Wizigmann-Voos S, Breier G, Risau W, Plate K. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358-64, 1995.
103. Woodward E, Eng C, McMahon R, Voutilainen R, Affara N, Ponder B, Maher E. Genetic predisposition to phaeochromocytoma: Analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet (in press).
104. Yao M, Latif F, Orcutt M, Kuzmin I, Stackhouse T, Zhou F, Tory K, Duh F, Richards F, Maher E, LaForgia S, Huebner K, Le Paslier D, Linehan M, Lerman M, Zbar B. von Hippel-Lindau disease: Identification of deletion mutations by pulsed field gel electrophoresis. Hum Genet 92: 605-614, 1993.
105. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HPH, Tisherman S, Mulvihill JJ, Gross D, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CHM, Linehan MW, Lerman M. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8: 348-57, 1996.
106. Zhuang Z, Bertheau P, Emmert-Buck M, Liotta L, Gnarra J, Linehan W, Lubensky I. A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol 146: 620-25, 1995.
107. Zhuang Z, Gnarra JR, Dudley CF, Zbar B, Linehan WM, Lubensky IA. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Mod Pathol 9: 838-42, 1996.